3 unchanged sentences
10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: On May 13, 2026, the Company and Christopher Downs,
+Added: the Company’s Senior Vice President – Finance, entered into a Separation and Severance Agreement, which memorializes the terms
+Added: Down’s separation from service with the Company.
+Added: Pursuant to the agreement, subject to Mr.
+Added: Down’s timely execution,
+Added: non-revocation, and compliance with the agreement’s terms, the Company will provide severance benefits, equal to six months of Mr.
+Added: Down’s current annualized base salary, paid in accordance with the Company’s regular payroll cycle.
INDEX TO EXHIBITS
−Removed: Certificate of Change filed with the State of Nevada (incorporated by reference to Exhibit 3.1 of the Form 8-K filed July 22, 2025)
+Added: Placement Agency Agreement dated May 4, 2026 by and between CNS Pharmaceuticals, Inc.
+Added: and A.G.P./Alliance Global Partners (filed as Exhibit 1.1 to the Company’s Form 8-K filed May 4, 2026)
+Added: Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Company’s
+Added: Form 8-K filed May 4, 2026)
+Added: Employment Agreement between Steve O’Loughlin and CNS Pharmaceuticals, Inc.
+Added: dated February 10, 2026 (filed as Exhibit 10.1 to the Company’s Form 8-K filed February 17, 2026)
+Added: Employment Agreement between Christopher Downs and CNS Pharmaceuticals, Inc.
+Added: dated February 13, 2026 (filed as Exhibit 10.2 to the Company’s Form 8-K filed February 17, 2026)
+Added: Employment Agreement between Lynne Kelley and CNS Pharmaceuticals, Inc.
+Added: dated February 26, 2026 (filed as Exhibit 10.1 to the Company’s Form 8-K filed March 2, 2026)
+Added: Separation and Severance Agreement between Sandra Silberman and CNS Pharmaceuticals, Inc.
+Added: dated February 27, 2026 (filed as Exhibit 10.2 to the Company’s Form 8-K filed March 2, 2026)
+Added: Employment Agreement between Eric Faulkner and CNS Pharmaceuticals, Inc.
+Added: dated February 10, 2026 (filed as Exhibit 10.19 to the Company’s Form 10-K filed March 31, 2026)
+Added: Form of Securities Purchase Agreement dated May 4, 2026 (filed as Exhibit 10.1 to the Company’s Form 8-K filed May 4, 2026)
+Added: Form of Registration Rights Agreement dated May 4, 2026 (filed as Exhibit 10.2 to the Company’s Form 8-K filed May 4, 2026)
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
19 unchanged sentences
CNS PHARMACEUTICALS, INC.
−Removed: /s/ John Climaco
−Removed: Chief Executive Officer and Director
−Removed: November 14, 2025
+Added: /s/ Rami Levin
+Added: Chief Executive Officer, President
(Principal Executive Officer)
−Removed: /s/ Christopher Downs
+Added: /s/ Steve O’Loughlin
Chief Financial Officer
−Removed: November 14, 2025
−Removed: Christopher Downs
+Added: Steve O’Loughlin
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.